Clinical Trial Update: S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports the completion of a study evaluating topotecan with or without aflibercept in extensive-stage small cell lung cancer, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Aflibercept (Aflibercept)
• Topotecan (topotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-04-04